Thymidine Kinase 2 Deficiency (TK2D) is a progressive mitochondrial disorder characterized by muscle weakness and respiratory impairment. The therapeutic landscape is evolving rapidly, fueled by increased rare disease research investments and novel treatment approaches. Industry leaders such as Modis Therapeutics, Ultragenyx, and ReGenX Biosciences are pioneering potential breakthrough therapies to address this critical unmet medical need.

Explore TK2D Market Insights Now:
https://www.delveinsight.c...